Activity Report

ESC COUNCIL OF CARDIO-ONCOLOGY
FISCAL YEAR 2022 (APRIL 2021 – MARCH 2022)
Highlights from 2021-2022

- **Over 1,900 members** from multiple disciplines.

- Five **Cardio-Oncology Clinical Case Talk** videos produced.

- Collaborated with other ESC Constituent bodies on scientific publications, joint sessions at congress and workshops.

- **Four webinars** developed in different areas of cardio-oncology, including collaborations with external societies.

- One of the partners of the **RESILIENCE** project.
Council of Cardio-Oncology Nucleus
2020-2022

Thomas Suter
Chairperson

Alexander Lyon
Chairperson-Elect

Riccardo Asteggiano
Past-Chairperson

Peter van der Meer
Treasurer

Teresa Lopez Fernandez
Secretary

Rudolf De Boer
Liaison Officer

Ciro Santoro
Communications Coordinator

Jeroen Bax
Nucleus Member

Christopher Plummer
Nucleus Member

Geeta Gulati
Nucleus Member
Membership

By March 2022, the Council had attracted over 1,900 members from multiple disciplines.

The Council reaches out to members via its e-newsletter, and it also promotes discussions between different healthcare professionals on its Facebook group: in March 2022 this group had 4900 members.

In February 2022, in conjunction with World Cancer Day, the Council highlighted a selection of ESC resources on cardio-oncology which were made free to access for a limited period.

Congresses

The Council was involved in helping to build the cardio-oncology sessions during ESC Congress 2021 – a digital experience.

- Cardiology and Cancer
- Cardiotoxicity of cancer therapy: a clinical update
- Hot Line - PRONOUNCE
- Impact on diagnosis: role of AI in cardio-oncology

Joint Sessions

The Council collaborated with the Association for Acute CardioVascular Care to develop a joint session during the ACVC 2022 online Congress:

Acute cardiovascular care meets cardio-oncology

Other

The Council also contributed to a joint workshop with the Heart Failure Association: Overcoming the challenges in immune therapies in Cardio-Oncology. The objective of this workshop was defined as: ‘to develop and publish a Position Statement on the pathophysiology and clinical management of cardiovascular toxicities caused by immune-targeted therapies in cancer patients including immune checkpoint inhibitors, CAR-T cell therapies and TIL therapies.’

A second collaborative workshop was held in March 2022 on the Impact of Exercise on heart function in cancer patients with the objective of developing and publishing a Position Statement on the pathophysiology and mechanism of the benefits of exercise in clinical management of cardiovascular
toxicities caused by chemotherapy and targeted therapies in cancer patients including immune checkpoint inhibitors, CAR-T cell therapies and TIL therapies.

Education

Clinical Case Talks
In 2021-2022 the Council added another five videos to its series of clinical case talks.

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>20/09/2021</td>
<td>Carfilzomib-induced cardiovascular toxicity</td>
</tr>
<tr>
<td>16/08/2021</td>
<td>Prevention and mitigation of LV dysfunction</td>
</tr>
<tr>
<td>06/07/2021</td>
<td>Management of hypertension in a cancer patient</td>
</tr>
<tr>
<td>07/06/2021</td>
<td>A Cancer Patient Developing Heart Failure</td>
</tr>
<tr>
<td>21/05/2021</td>
<td>Cardiovascular Monitoring in a Patient with Breast Cancer</td>
</tr>
</tbody>
</table>
## Webinars

The Council organised four webinars in 2021-2022:

<table>
<thead>
<tr>
<th>Date</th>
<th>Title</th>
<th>Presenters</th>
<th>Host</th>
<th>Attendees</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 2021</td>
<td>Anticoagulation issues in cancer patients</td>
<td>Giuseppe Boriani, Dimitrios Farmakis</td>
<td>Riccardo Asteggiano</td>
<td>598</td>
</tr>
<tr>
<td>September 2021</td>
<td>Cancer associated thrombosis: have DOACs changed daily practice?</td>
<td>Ciro Santoro, Geeta Gulati</td>
<td>Sebastian Szmit, Anna Falanga</td>
<td>431</td>
</tr>
<tr>
<td>February 2022</td>
<td>Prevention of radiotherapy-induced cardiovascular disease</td>
<td>Marianne Aznar, Ciro Santoro</td>
<td>Jutta Bergler-Klein</td>
<td>394</td>
</tr>
<tr>
<td>March 2021</td>
<td>How to organise a cancer survivorship programme</td>
<td>Helena van der Pal, Anita Arnold</td>
<td>Thomas Suter, Evandro de Azambuja</td>
<td>TBC</td>
</tr>
</tbody>
</table>

- Cancer patients have both increased thromboembolic and haemorrhagic risk:
  - due to cancer physiopathology itself
  - due to cancer treatment
- A.Fib. may be:
  - Associated to cancer for epidemiology issues
  - Due to cancer for physiopathology issues
  - Due to cancer treatment
  - CHA2DS2-Vasc Score although not validated in cancer patients could be used for thromboembolic risk stratification
  - High HAS-BLED (≥ 3) not contraindicates anticoagulation, but suggests removal of modifiable risk factors and increased surveillance.
  - Absolute contraindications to anticoagulation must be followed.
- Cancer-associated thrombosis is the second-leading cause of death in cancer.
Scientific Documents
The Council has been involved in the development of the following scientific documents during 2021-2022:

**Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases** -> Published October 2020, European Heart Journal of Acute Cardiovascular Care

Advocacy
The Council, in collaboration with the ESC Advocacy Committee, participated in the event: *Cancer Cardiovascular Co-morbidities and complications: the opportunities for action*, jointly organised by the MEP Heart Group and the Challenge Cancer EU Parliamentary Intergroup on 9 December 2021

Resilience
The Council is one of the partners in the RESILIENCE project. This is a European Commission-funded project aimed at reducing the prevalence of heart failure in cancer survivors. The latest project newsletter can be read [here](#).

Guidelines
The Council continues to be involved in the development of these guidelines:

- from the European Hematology Association on “Cardiovascular toxicity in older adults with hematologic malignancies”
- from the European Respiratory Society (ERS) and the European Society of Thoracic Surgery (ESTS) on ‘ERS/ESTS Clinical Practice Guideline on Fitness for Tumour-specific Treatments of Lung Cancer’